Information:
Error:
ID
34327
Description
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01170962
Link
https://clinicaltrials.gov/show/NCT01170962
Keywords
Versions (1)
- 1/16/19 1/16/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 16, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Hepatitis C Virus NCT01170962
Eligibility Hepatitis C Virus NCT01170962
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C Virus NCT01170962
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
subjects chronically infected with hcv genotype 1
boolean
ID.2
Item
non-responder to prior therapy with peginterferon alfa and ribavirin
boolean
ID.3
Item
hcv rna viral load of ≥ 100,00 iu/ml
boolean
ID.4
Item
results of a liver biopsy ≤ 24 months prior to randomization consistent with chronic hcv infection; for compensated cirrhotics can be any time prior to randomization (compensated cirrhotics will be capped at 10% of randomized study population)
boolean
ID.5
Item
ultrasound, ct scan or mri results 12 months prior to randomization that do not demonstrate hepatocellular carcinoma
boolean
ID.6
Item
body mass index (bmi) of 18 to 35 kg/m2
boolean
ID.7
Item
positive for hepatitis b infection (hbsag) or hiv-1/hiv-2 antibody at screening
boolean
ID.8
Item
evidence of medical condition associated with chronic liver disease other than hcv
boolean
ID.9
Item
evidence of decompensated cirrhosis based on radiologic criteria or biopsy
boolean